Research programme: designed repeat proteins - Molecular Partners/Allergan

Drug Profile

Research programme: designed repeat proteins - Molecular Partners/Allergan

Alternative Names: AGN-151200; DARPin therapies for eye disorders - Molecular Partners/Allergan; MP 0260; MP0260 (dual anti-vascular endothelial growth factor A [VEGF-A]/anti-platelet derived growth factor B [PDGF-B] DARPin); Multi‐VEGF/PDGF DARPin - Allergan/Molecular Partners

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Partners AG
  • Developer Allergan; Molecular Partners AG
  • Class Eye disorder therapies; Proteins
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Age-related macular degeneration; Eye-Disorders

Most Recent Events

  • 19 Feb 2018 Allergen exercises the third option to develop and commercialise DARPin® product candidates for Eye disorders
  • 14 Feb 2018 Early research is ongoing for Eye disorders and Age-related macular degeneration in Switzerland (Molecular Partners pipeline, February 2018)
  • 03 Jan 2018 Allergan exercised two options to develop and commercialise DARPin® candidates for Eye disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top